Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

In today’s episode, we had the pleasure of speaking with Justin Taylor, MD, an associate professor in the Division of Hematology at the University of Miami Miller School of Medicine, about the growing role of artificial intelligence in cancer information–seeking and what this means for clinicians caring for patients with hematologic malignancies. Dr Taylor’s recent work explores how patients are increasingly turning to AI tools to better understand their diagnoses and treatments, and why oncologists must be aware of the accuracy, limitations, and clinical implications of these technologies.

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Lee is the chief oncology/hematology fellow at Weill Cornell Medicine in New York, New York.

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In part 1 of this 3-part series, Dr Terris discussed the prevalence of bladder cancer in women, as well as reasons for diagnostic disparities that contribute to poor treatment outcomes. She noted that this disease is often diagnosed at later stages in women than in men, often resulting in diagnoses of more advanced disease and translating to poorer outcomes. She added that although female patients represent a minority of those with urothelial carcinoma.

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.